FIG 3.

Potency of host-dependent inhibition against different variants of SARS-CoV-2 remains unaffected. Camostat (A) and bafilomycin A1 (B) were tested against SARS-CoV-2 D641G, B.1.117 (i.e., Alpha), B.1.351 (i.e., Beta) or B.1.1.529 (i.e., Omicron) PsV variants using HeLa cells expressing ACE2 but lacking TMPRSS2 or Vero cells expressing both ACE2 and TMPRSS2. All experiments were conducted in quadruplicates, at the minimum (n = 4 to 5). (C) The half-maximal inhibitory concentration (IC₅₀) of Camostat and bafilomycin A1 against several SARS-CoV-2 PsVs variants using HeLa cells expressing ACE2 but lacking TMPRSS2 or Vero cells expressing both ACE2 and TMPRSS2 was calculated using Prism 9 (GraphPad). All experiments were conducted in quadruplicates, at the minimum (n = 4 to 13).